BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 21059637)

  • 21. Identification of a subgroup with worse prognosis among patients with poor-risk testicular germ cell tumor.
    Kojima T; Kawai K; Tsuchiya K; Abe T; Shinohara N; Tanaka T; Masumori N; Yamada S; Arai Y; Narita S; Tsuchiya N; Habuchi T; Nishiyama H
    Int J Urol; 2015 Oct; 22(10):923-7. PubMed ID: 26094715
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paclitaxel+BEP (T-BEP) regimen as induction chemotherapy in poor prognosis patients with nonseminomatous germ cell tumors: a phase II study.
    Tryakin A; Fedyanin M; Kanagavel D; Fainstein I; Sergeev J; Polockij B; Matveev V; Zakharova T; Garin A; Tjulandin S
    Urology; 2011 Sep; 78(3):620-5. PubMed ID: 21764427
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-Term Survival of Good-Risk Germ Cell Tumor Patients After Postchemotherapy Retroperitoneal Lymph Node Dissection: A Comparison of BEP × 3 vs. EP × 4 and Treating Institution.
    Cary C; Jacob JM; Albany C; Masterson TA; Hanna NH; Einhorn LH; Foster RS
    Clin Genitourin Cancer; 2018 Apr; 16(2):e307-e313. PubMed ID: 29104087
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours.
    Lawrence NJ; Chan H; Toner G; Stockler MR; Martin A; Yip S; Wong N; Yeung A; Mazhar D; Pashankar F; Frazier L; McDermott R; Walker R; Tan H; Davis ID; Grimison P;
    BMC Cancer; 2018 Aug; 18(1):854. PubMed ID: 30157803
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II study.
    Selle F; Wittnebel S; Biron P; Gravis G; Roubaud G; Bui BN; Delva R; Bay JO; Fléchon A; Geoffrois L; Caty A; Soares DG; de Revel T; Fizazi K; Gligorov J; Micléa JM; Dubot C; Provent S; Temby I; Gaulet M; Horn E; Brindel I; Lotz JP
    Ann Oncol; 2014 Sep; 25(9):1775-1782. PubMed ID: 24894084
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First-line combination chemotherapy with cisplatin, etoposide and ifosfamide for the treatment of disseminated germ cell cancer: re-evaluation in the granulocyte colony-stimulating factor era.
    Tanaka H; Yuasa T; Fujii Y; Sakura M; Urakami S; Yamamoto S; Masuda H; Fukui I; Yonese J
    Chemotherapy; 2013; 59(6):441-6. PubMed ID: 25060582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment of non-testicular germ cell tumors in children and adolescents with BEP and VIP: initial results of the MAKEI 89 therapy study].
    Göbel U; Bamberg M; Engert J; Gnekow AK; Haas HJ; Jürgens H; Kühl J; Lenard HG; Lumenta C; Niethammer D
    Klin Padiatr; 1991; 203(4):236-45. PubMed ID: 1719267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group.
    Hartmann JT; Gauler T; Metzner B; Gerl A; Casper J; Rick O; Horger M; Schleicher J; Derigs G; Mayer-Steinacker R; Beyer J; Kuczyk MA; Bokemeyer C;
    J Clin Oncol; 2007 Dec; 25(36):5742-7. PubMed ID: 18089869
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors.
    Christian JA; Huddart RA; Norman A; Mason M; Fossa S; Aass N; Nicholl EJ; Dearnaley DP; Horwich A
    J Clin Oncol; 2003 Mar; 21(5):871-7. PubMed ID: 12610187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study.
    Necchi A; Mariani L; Di Nicola M; Lo Vullo S; Nicolai N; Giannatempo P; Raggi D; Farè E; Magni M; Piva L; Matteucci P; Catanzaro M; Biasoni D; Torelli T; Stagni S; Bengala C; Barone C; Schiavetto I; Siena S; Carlo-Stella C; Pizzocaro G; Salvioni R; Gianni AM
    Ann Oncol; 2015 Jan; 26(1):167-172. PubMed ID: 25344361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.
    Motzer RJ; Nichols CJ; Margolin KA; Bacik J; Richardson PG; Vogelzang NJ; Bajorin DF; Lara PN; Einhorn L; Mazumdar M; Bosl GJ
    J Clin Oncol; 2007 Jan; 25(3):247-56. PubMed ID: 17235042
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Case of far-advanced retroperitoneal extra-gonadal germ cell tumor responding to intensive treatment including multi-drug chemotherapy with peripheral blood stem cell transplantation and residual tumor removal].
    Yamashita T; Morozumi M; Takagi D; Yoshinaga A; Ishii N; Matsuda T; Terao T; Yamada T
    Nihon Hinyokika Gakkai Zasshi; 2010 Mar; 101(3):565-9. PubMed ID: 20387517
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Result of treatment for advanced germ cell tumor in the last decade].
    Ishioka J; Kageyama Y; Inoue M; Fukui N; Numao N; Saito K; Ichiyanagi N; Tanak M; Hyochi N; Fukuda H; Higashi Y
    Nihon Hinyokika Gakkai Zasshi; 2010 Mar; 101(3):539-46. PubMed ID: 20387513
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dose chemotherapy followed by hematological support: experience in the treatment of germ cell tumors.
    Pico JL; Fadel E; Ibrahim A; Bourhis JH; Droz JP
    Bull Cancer; 1995; 82 Suppl 1():56s-60s. PubMed ID: 7542945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom.
    Fosså SD; Kaye SB; Mead GM; Cullen M; de Wit R; Bodrogi I; van Groeningen CJ; De Mulder PH; Stenning S; Lallemand E; De Prijck L; Collette L
    J Clin Oncol; 1998 Feb; 16(2):716-24. PubMed ID: 9469362
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.
    Albers P; Siener R; Krege S; Schmelz HU; Dieckmann KP; Heidenreich A; Kwasny P; Pechoel M; Lehmann J; Kliesch S; Köhrmann KU; Fimmers R; Weissbach L; Loy V; Wittekind C; Hartmann M;
    J Clin Oncol; 2008 Jun; 26(18):2966-72. PubMed ID: 18458040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term outcome of patients with clinical stage I high-risk nonseminomatous germ-cell tumors 15 years after one adjuvant cycle of bleomycin, etoposide, and cisplatin chemotherapy.
    Vidal AD; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
    Ann Oncol; 2015 Feb; 26(2):374-7. PubMed ID: 25392157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of intermediate-prognosis germ-cell cancer: results of a phase I/II study of Taxol-BEP.
    de Wit R; Louwerens M; de Mulder PH; Verweij J; Rodenhuis S; Schornagel J
    Int J Cancer; 1999 Dec; 83(6):831-3. PubMed ID: 10597204
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term outcomes with intensive induction chemotherapy (carboplatin, bleomycin, vincristine and cisplatin/bleomycin, etoposide and cisplatin) and standard bleomycin, etoposide and cisplatin in poor prognosis germ cell tumours: A randomised phase II trial (ISRCTN53643604).
    Cafferty FH; White JD; Shamash J; Hennig I; Stenning SP; Huddart RA;
    Eur J Cancer; 2020 Mar; 127():139-149. PubMed ID: 32007714
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Experience with bleomycin, etoposide, cisplatin (BEP) and alternating cisplatin, cyclophosphamide, doxorubicin (CISCA(II))/vinblastine, bleomycin (VB(IV)) regimens of chemotherapy in poor-risk nonseminomatous germ cell tumors.
    Culine S; Théodore C; Bekradda M; Farhat F; Terrier-Lacombe MJ; Droz JP
    Am J Clin Oncol; 1997 Apr; 20(2):184-8. PubMed ID: 9124197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.